Innovative Eyewear (NASDAQ:LUCYW) & NovoCure (NASDAQ:NVCR) Critical Contrast

NovoCure (NASDAQ:NVCR) and Innovative Eyewear (NASDAQ:LUCYW) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, dividends and institutional ownership.

Insider and Institutional Ownership

84.6% of NovoCure shares are held by institutional investors. 6.6% of NovoCure shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations and price targets for NovoCure and Innovative Eyewear, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NovoCure	1	4	2	0	2.14
Innovative Eyewear	0	0	0	0	0.00

NovoCure currently has a consensus target price of $21.20, suggesting a potential upside of 21.27%. Given NovoCure’s stronger consensus rating and higher possible upside, equities analysts plainly believe NovoCure is more favorable than Innovative Eyewear.

Profitability

This table compares NovoCure and Innovative Eyewear’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NovoCure	-21.25%	-44.00%	-15.85%
Innovative Eyewear	N/A	N/A	N/A

Earnings and Valuation

This table compares NovoCure and Innovative Eyewear”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NovoCure	$655.35 million	3.11	-$136.23 million	($1.30)	-13.45
Innovative Eyewear	$2.98 million	N/A	N/A	N/A	N/A

Innovative Eyewear has lower revenue, but higher earnings than NovoCure.

Summary

NovoCure beats Innovative Eyewear on 6 of the 9 factors compared between the two stocks.

About NovoCure

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

About Innovative Eyewear

Innovative Eyewear, Inc. develops and sells smart eyeglasses and sunglasses. The company's flagship product is Lucyd Lyte glasses that enable the wearer to listen to music, take and make calls, and use voice assistants and ChatGPT to perform various smartphone tasks hands-free. It also offers smart eyewear under the Lyte XL brand; and Nautica Powered by Lucyd smart eyewear collection and various branded accessories, including a power brick, cleaning cloth, and a slipcase adorned. In addition, the company provides Vyrb, a social media application that enables the user to receive and send posts through Lucyd Lyte smart glasses with an individual's voice; and Lucyd app for iOS and Android to provide voice access to ChatGPT in Lucyd eyewear. It sells its products through various e-commerce and retail channels. Innovative Eyewear, Inc. has a license agreement with Lucyd Ltd. The company was incorporated in 2019 and is headquartered in North Miami, Florida.